732. Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

作者
David Altarac,Alita A. Miller,Sarah M. McLeod,Adam B. Shapiro,Khurram Z. Rana,Drew E. Lewis,Gabrielle Poirier,Daria Chabas
出处
期刊:Open Forum Infectious Diseases [Oxford University Press]
卷期号:9 (Supplement_2) 被引量:3
标识
DOI:10.1093/ofid/ofac492.023
摘要

Abstract Background SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC, which is a cause of severe infections with substantial mortality. ATTACK evaluated the efficacy and safety of SUL-DUR versus colistin (COL) in patients with serious ABC infections. Methods Part A was a randomized, blinded non-inferiority study (SUL-DUR versus COL) in ABC pneumonia or bacteremia; Part B was an open label study (SUL-DUR only) that enrolled patients with ABC infections who did not tolerate COL or whose pathogens were resistant to COL (COL-R). All subjects received imipenem/cilastatin as background therapy. Primary endpoint included 28-day all-cause mortality (ACM) in Part A patients with carbapenem-resistant ABC at baseline (CRABC m-MITT). Clinical and microbiologic outcomes were measured at the End of Therapy (EOT), Test of Cure (TOC) and Late Follow-up (LFU) visits in CRABC m-MITT patients. In this study, COL-R was defined as MIC ≥ 4 µg/ml and SUL-DUR-non-susceptible (NS) was defined as MIC ≥ 8 µg/ml. Results SUL-DUR was non-inferior to COL in 28-day ACM; 19.0% SUL-DUR versus 32.3% in the COL group (Table 1). SUL-DUR therapy resulted in statistically significant higher clinical cures at EOT and TOC. Similarly, a significant treatment difference in microbiological favorable assessment was observed at EOT and TOC (24.4% and 26.3%, respectively, in Part A). Similar mortality differences were observed in subgroups including infection type, severity of illness, mechanical ventilation, and duration of stay of at least 5 days in the ICU prior to starting study treatment (Table 2). All 149 baseline ABC isolates from CRABC m-MITT patients were multi-drug resistant; the SUL-DUR MIC50/90 was 2/4 µg/ml (range of 0.25 – 8 µg/ml). At baseline 33% of ABC infections were polymicrobial. Conclusion In ATTACK, patients treated with SUL-DUR had lower mortality, higher clinical cure rates and significantly greater microbiologically favorable outcomes than those treated with COL. The correlation between clinical and microbiologic outcomes provides additional evidence that, if approved, SUL-DUR could be an important therapeutic option for Acinetobacter infections including carbapenem-resistant and multidrug-resistant strains. Disclosures David Altarac, MD, MPA, Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds Alita Miller, PhD, Entasis Therapeutics: Employee Sarah McLeod, PhD, Entasis Therapeutics: Employee Adam B. Shapiro, Ph.D, Entasis Therapeutics: Employee|Entasis Therapeutics: Stocks/Bonds Khurram Rana, PharmD, Entasis Therapeutics: Employee|Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds Drew Lewis, MD, MTM&H, Entasis Therapeutics: employee|Entasis Therapeutics: employee|Entasis Therapeutics: Stocks/Bonds|Entasis Therapeutics: Stocks/Bonds Gabrielle Poirier, BS, Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds Daria Chabas, BS, Entasis Therapeutics: Ownership Interest|Entasis Therapeutics: Stocks/Bonds.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Tmac完成签到,获得积分10
刚刚
云舒完成签到 ,获得积分10
刚刚
大力怀绿完成签到,获得积分10
刚刚
yyy完成签到,获得积分10
刚刚
希屿完成签到,获得积分10
刚刚
Ning完成签到,获得积分10
1秒前
yangyangyang完成签到,获得积分0
1秒前
sens完成签到,获得积分10
1秒前
1秒前
昏睡的洋葱完成签到,获得积分10
1秒前
无花果的应助被呢喃采纳,获得10
2秒前
鸟窝的应助被li采纳,获得10
2秒前
科目三的应助被搞怪花生采纳,获得10
2秒前
小白完成签到 ,获得积分10
2秒前
牛马发布了新的文献求助10
2秒前
米多奇完成签到,获得积分10
2秒前
鱼跃完成签到,获得积分10
3秒前
呵呵喊我完成签到,获得积分10
3秒前
ZhangCS完成签到,获得积分10
3秒前
张张完成签到,获得积分10
3秒前
劳模老徐完成签到 ,获得积分10
3秒前
gyq完成签到,获得积分10
3秒前
Axel发布了新的文献求助10
3秒前
3秒前
派兀派完成签到,获得积分10
4秒前
oyy318完成签到,获得积分10
4秒前
稳重的水池完成签到,获得积分10
4秒前
歪比巴卜完成签到 ,获得积分10
4秒前
4秒前
单纯草丛完成签到,获得积分10
4秒前
seven完成签到,获得积分10
4秒前
DPBHX完成签到,获得积分10
5秒前
搜集达人的应助被kong采纳,获得10
5秒前
甜甜镜子完成签到,获得积分10
5秒前
ryoung3完成签到 ,获得积分10
5秒前
liquidwy完成签到,获得积分10
6秒前
Yuan88发布了新的文献求助10
6秒前
LL完成签到,获得积分10
6秒前
6秒前
CCCCCL完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173729
求助须知:如何正确求助?哪些是违规求助? 9565870
关于积分的说明 21782999
捐赠科研通 7767898
什么是DOI,文献DOI怎么找? 3431625
关于科研通互助平台的介绍 2555879
邀请新用户注册赠送积分活动 2476903